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goal, the proportion of and time to A1C increasing above 7% (relapse) were ana-
lyzed. Cox proportional hazard models were estimated to identify demographic
and clinical predictors of A1C goal achievement and relapse. RESULTS: Basal insu-
lin initiators with T2DM (n13,373) were on average 60 years old, 50.5% were fe-
males, 59.5% had A1C8%, 59.7% were obese, and more than half used metformin
(52.7%) or sulfonylureas (53.4%) before insulin initiation. A total of 5844 (44%) pa-
tients reached goal within one year since initiation, and 7699 (58%) reached goal
during the 2.5-year follow-up. The median time to reaching goal was 536 days
(95% CI: 510-562). Older age, being white or male, lower baseline A1C values and no
OAD use before insulin initiation were associated with significantly higher rates of
reaching goal. Among the patients who reached goal, 57.6% relapsed, and the me-
dian time from reaching the goal to relapse was 398 days (95% CL: 383-417). Being
Hispanic, higher baseline A1C values and OAD use at baseline were associated with
significantly higher rates of relapse. CONCLUSIONS: A high proportion of T2DM
patients did not have adequate glycemic control after initiating basal insulin. Var-
ious factors existing prior to insulin initiation were related to successful treatment
of T2DM. Further research into how to improve glycemic control is encouraged.
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OBJECTIVES: The aim of the current study was to examine patient characteristics,
treatment patterns, and burden of type 2 diabetes (T2D) adult patients with and
without comorbid obesity in France, Germany, and UK. METHODS: Data from the
EU National Health and Wellness Survey were used. Demographics, HbA1c levels,
prevalence of hypertension, high cholesterol, T2D current treatments, and health
outcomes (SF-12) were assessed for all T2D patients (France: n642, Germany:
n1,019, UK: n932). Patients with and without obesity (BMI30) were also
compared. RESULTS: Obesity rates within T2D were 47%, 51%, and 56% in France,
Germany, and UK, respectively. Pooling countries, T2D patients had 2.6 greater
odds of obesity than non-T2D patients and the proportion of obese T2D patients
increased from 44% to 51 % (2006 to 2010). The rates of being uncontrolled (HbA1c
7%) were higher among obese T2D (20% vs. 17%, p.05), but the difference was
only significant in Germany (24% vs. 19%, p.05). The use of insulin was signifi-
cantly higher (23% vs. 16%, p.05) among obese patients, but this difference was
only significant in Germany and UK and not in France. Hypertension and high
cholesterol were significantly more prevalent in obeseT2D patients (65% vs. 51%
and 40% vs. 35%, respectively, ps.05). Hypertension differences were significant
for all countries while high cholesterol differences were only significant in Ger-
many. Obesity was associated with significantly worse physical quality of life
(France: 40 vs. 44; Germany: 39 vs. 44; UK: 37 vs. 42, respectively p.05).
CONCLUSIONS: A substantial number of T2D patients are obese. Obesity was as-
sociated with worse quality of life, and worse health outcomes including poor
glycemic control (in the case of Germany), hypertension and high cholesterol; all
these factors are CV disease risk factors. Improving obesity management will be
the key to improve health and outcomes in T2D.
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OBJECTIVES: We analyzed the impact of implementing a preauthorization policy
for Rosiglitazone (an anti-diabetic drug) use on the eligibility requirements (treat-
ment initiation and discontinuation) and patients’ HbA1c levels. METHODS: We
compared treatment patterns of diabetic patients prior to and after an implemen-
tation of a preauthorization policy for Rosiglitazone use. Data were obtained from
the Maccabi Healthcare Services’ (the second largest HMO in Israel) registry of
diabetic patients. We compared adherence to eligibility criteria in a group of pa-
tients who received Rosiglitazone without preauthorization (N1362) and patients
who received the medication with preauthorization (N824). The criteria for re-
ceiving Rosiglitazone in both groups were identical and included prior medication
[experienced patients who received drug from the sulphonylurea class in combi-
nation with Metformin for at least a three months period], and laboratory criterion
[HbA1c levels higher than 8% during the past three months]. Treatment should be
continued only if within three months from treatment initiation, the patient ac-
quired at least three packages of Rosiglitazone and a decrease of 0.8% in HbA1c
values was observed. RESULTS: Implementing preauthorization policy increased
the fulfillment of the eligibility criteria (medication and laboratory) for drug use by
41% [from 25% of patients without preauthorization to 35% with preauthorization
(p0.001)]. With regard to meeting the requirements for treatment continuation
after a three month period, there was an increase of only 6.4% in the fulfillment of
both requirements (from 37.6% to 40.0% prior and after preauthorization, respec-
tively). The average decrease in patients’ HbA1c levels was 0.6% and was similar in
both patients with and without preauthorization. CONCLUSIONS: Implementing
preauthorization for Rosigitazone resulted in an increase in meeting the require-
ments for treatment initiation and a marginal change in treatment continuation
criteria, but this increase was insufficient to achieve HbA1c target levels. However,
patients’ health was not negatively affected by this policy.
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OBJECTIVES: Type 2 diabetes, is a disease with a rising prevalence worldwide. A
major burden of this disease would be shared by developing countries like Iran.
Medications for diabetes mellitus need to be taken for the entire life and factors like
efficacy, side effects, drug interactions and cost of therapy should be consider. This
study was designed to evaluate the prescription pattern of anti-diabetic drugs in
T2DM patients from 2006 to 2009 in Iran. METHODS: A retrospective study was
undertaken on insured prescriptions during 4 years. All insured prescriptions
which were collected in special software called Rx Analyst during the study period
in the NCRUD were reviewed for prescriptions included anti-diabetic drugs. The
brand names of drugs in prescriptions were decoded to generic names, according to
standard Iran drug list.RESULTS:A total of 261,110,666 prescriptions were assessed
in which 11,637,224 were detected to be included at least one dosage form of anti-
diabetic medications. From all, 1,376,750 prescriptions had at least one injection
form of Insulin and 10,260,474 of oral anti diabetic drugs. Trend evaluation of
prescribing showed that the total number anti-diabetic medications were in-
creased from 16,158,375 in 2006 to 4,268,444 in 2009. The portion of prescriptions
with Insulin was 8%, 9%, 13% and 9% and for oral anti-diabetic drugs, it was 59%,
66%, 71% and 72%in 2006, 2007, 2008 and 2009, respectively. The total cost of Insulin
during study period was 17,134,032 US$ and for oral anti-diabetic drugs was
84,682,039 US$ from national sales data. CONCLUSIONS: According to national
sales data, total cost of anti-diabetic medications is about 100,00 times more than
cost of these drugs in prescriptions. This huge gap shows irrational use of such
medications. A multi interventional policy including educational, regulatory, man-
agerial and financial strategies for professions and public should be planed to
promote rational use of anti-diabetic medications.
PDB70
LOW-DOSE PIOGLITAZONE UTILISATION IN PATIENTS WITH TYPE 2 DIABETES
MELLITUS IN THE UNITED KINGDOM
Zhao C, Zhang Q, Davies MJ, Steinberg H
Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA
OBJECTIVES: To evaluate the distribution of pioglitazone (PIO) daily dose pre-
scribed by physicians for patients with type 2 diabetes mellitus (T2DM).METHODS:
In a retrospective cohort study using the UK MediPlus database, patients with
diagnosed T2DM who received PIO prescription between July 2008– June 2009 (ob-
servation period) were included. Medical records from 07/2007–06/2008 were used
to assess baseline conditions. Patients were grouped, according to prescriptions in
the observation period, as low-dose users who received PIO prescriptions of 15-mg
daily dose only or were down-titrated to 15 mg from a higher daily dose, and
high-dose users for the rest who received a 30 mg or higher daily dose. RESULTS:Of
1813 patients with T2DM who received a PIO prescription, 48% received at least one
15 mg prescription during the observation period. Among all PIO prescriptions,
39%, 40%, and 21% were in 15, 30, and 45 mg or higher daily dose, respectively. Per
study definitions 38% of the patients were classified as low-dose users and 62% as
high-dose users. Low-dose users were more likely to be female (56% vs. 40%) and
had a lower baseline prevalence of diabetic nephropathy (0% vs. 1%), compared to
high-dose users (p0.05). Low-dose PIO use was not associated with baseline prev-
alence of congestive heart failure, coronary artery disease, or bone fractures.
CONCLUSIONS: Low-dose PIO was prescribed in greater than one-third of PIO pre-
scriptions, regardless of patient age and major comorbidities. The reason(s) why
patients received low-dose PIO warrants further investigation.
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OBJECTIVES: This retrospective study compares annual expenditures among
T2DM patients according to treatment stage and renal function status (RFS) and
identifies determinants of costs.METHODS:T2DM patients’ records were extracted
from the EGB database, which contains ambulatory care claims for a representative
sample of the French population. Patients were classified according to treatment
stage: oral / GLP1 monotherapy, double therapy, triple therapy or insulin therapy
(either associated or not with other antidiabetics), and according to RFS (identified
using pharmacy, lab and consultation claims). Costs were estimated from the na-
tional insurance perspective and included all reimbursements except for hospitali-
sations. Annual expenditures were assessed by year (from 2005 to 2010), by treat-
ment stage and by RFS. Effects of treatment stages and RFS on expenditures by year
were analysed by means of generalised linear models, with matching on age and
gender. RESULTS: The number of patients ranged from 9,682 to 11,772 between
2005 and 2010. Annual average total reimbursements in 2010 were €3,279 (standard
error: 65.5) for monotherapy, €3,592 92.1 for double therapy, €3,803 157.2 for
triple therapy and €7,729 180.8 for insulin therapy. The same cost pattern was
found in previous years. The regression model showed that costs increased by a
ratio of 2.31 (p0.001) from monotherapy to insulin therapy, adjusted for socio-
demographic characteristics and co-treatments. Excess costs for insulin therapy
were mainly related to nursing care (increasing by a ratio of 12.16, p0.001), med-
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ical devices and pharmacy costs. Reimbursements for patients with declining renal
function were estimated at €4,933 368.9 for monotherapy, €4,521 350.8 for dou-
ble therapy, €4,191 497.9 for triple therapy and €13,768 1106.2 for insulin
therapy. CONCLUSIONS: Overall, ambulatory care costs increase with treatment
escalation and declining renal function amongst T2DM patients. Insulin therapy is
associated with substantial increased costs, related to pharmacy, nursing care and
medical device utilization.
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OBJECTIVES:Hypoglycaemia is a common adverse event associated with the man-
agement of both type 1 and type 2 diabetes. While many hypoglycaemic episodes
can be self-treated, more severe episodes can require emergency treatment and
hospitalisation. The objective of our study was to evaluate the burden of hypogly-
caemia on secondary care costs in England. METHODS: Data captured in Hospital
Episode Statistics (HES)* for the period between 2006 and 2009 was analysed to
estimate the trends in hospital episodes. The associated costs were estimated
using Hospital Resource Group (HRG) tariff prices in England for the respective
years. RESULTS: There were a total of 11,330 inpatient spells assigned an HRG for
hypoglycaemia in 2009, an increase of 17.0% from 2006 when there were 9,682
inpatient spells. In 2006 the average inpatient length of stay was 5.7 days, but by
2009 this figure had risen by 21.1% to 6.9 days. In 2006 the cost of hypoglycaemia
due to hospitalisation was £13.57 million. In 2009 this figure was £16.04 million,
representing an 18.2% increase in cost burden. In 2009 the average inpatient cost
was £1635, up 8.7% from 2006 when the average cost was £1504. Over the four year
period 2006-2009 there were a total of 41,717 inpatient spells due to hypoglycaemia
at a total cost of £58.44 million. CONCLUSIONS: Hypoglycaemia represents a sig-
nificant and increasing burden on hospital care in England. Given current cost
constraints in the NHS, prescribers should seek to use medications that reduce the
risk of hospitalisation due to hypoglycaemia.
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OBJECTIVES: Diabetes affects 3%-5% of total UK population and insulin is the larg-
est drug-class category used to treat the disease. A greater understanding of the
impact of different economic and epidemiological variables on total insulin sales
will help the healthcare system and pharmaceutical industry be more responsive
to demand and cost. METHODS: Generalized least squares regression with period
random effects was used on a pooled yearly data set (2001 to 2010) of variables. The
dependent variable was total yearly sales for insulin. The explanatory variables
included - size of population; incidence and prevalence of diabetes; estimated total
prescription (Rx) for insulin; and employee compensation per capita. The analysis
used yearly pooled, cross-sectional data from IDF and IHS Forecasting Database at
different time points to account for the variation in different variables. The total
population was obtained from OECD. The prevalence and incidence rates were
obtained from IDF for 2001, 2003, 2007 and 2010; average of previous year’s data-
points were used for years in which no data was provided. The main independent
variable was the total yearly prescription rate for insulin, calculated from data
derived from intrinsic Patient Flow Model. RESULTS:A direct correlation was found
between estimated total Rx for insulin, total population, and prevalence rates for
diabetes. The results can be summarized as: For every 1% rise in total estimated Rx
for Insulin and total population there is a 71% and 48% increase in insulin sales,
respectively. CONCLUSIONS: Based on our model, total Rx plays a major role in
determining the total sales for insulin. From a policy perspective, it will support UK
government’s diabetes related initiatives focusing on effective cost management.
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OBJECTIVES: To undertake resource re-allocation for improvements in service and
patient outcomes within a diabetes programme using PBMA. METHODS: UK Na-
tional Health Service organisations have to manage severe budget pressures. If
health outcomes for patients are to be maintained and improved, resources must
be (re)allocated efficiently and some disinvestment is inevitable. PBMA is an ideal
framework for these tasks as it is based on opportunity costs and maximisation of
benefits. The pilot PBMA exercise reported was undertaken in an English PCT in
2010. Data on the inputs and outputs of diabetes care received by patients was
collected and evaluated by a multidisciplinary group of commissioners, healthcare
staff and patient representatives. Through comparison of the data with other PCTs,
and a review of the literature concerning the effectiveness and cost-effectiveness
of current and proposed interventions within the programme, the multidisci-
plinary group identified opportunities for resource reallocation. RESULTS: In com-
parisons, the PCT had near average spending but with poor HbA1c outcomes, use of
glucose blood testing reagents was high - the third most costly prescribed item and
of overall drug spending. Reducing unnecessary spending on these in type II dia-
betes patients freed resource for specialist nurses to coach patients in optimal
diabetes control. CONCLUSIONS: Literature reporting successful implementation
of PBMA is uncommon and factors associated with success are setting, individuals
leading the initiative and buy-in of participants to the process. In this exercise
using detailed financial and outcomes data, implementing PBMA and gaining
buy-in of stakeholders resulted in a successful disinvestment decision, resource
reallocation and re-investment in diabetes services. The next important step is to
use PBMA to make a disinvestment decision alone and improve the process; reduc-
ing the burden of this complex, data-intensive decision-making framework, main-
taining transparency, equity and ethics. This may increase the adoption and suc-
cessful execution of PBMA.
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OBJECTIVES: To analyze the development in the medicines pricing regulation in
Republic of Macedonia during 2005 to 2010 and its impact on medicines
affordability. METHODS: Regulatory analysis of the changes in the medicines
prices regulation for the period 2005 to 2010 was applied. The affordability of the
medicines to the population was explored before the after the new regulation
introduction. Affordability was evaluated through the comparison of the cost of
therapy of the most frequent diseases with the inhabitants wages. For comparison
purposes, the average monthly wages in January 2005 (7.999,00 MKD) and in Janu-
ary 2010 (14.914,00 MKD) were used as announced by the UJP (Public Revenue Office
of Macedonia). The statistical test used was Wilcoxon Matched Pais Test. RESULTS:
The unified medicines prices were established in 2007 based on ex-factory price,
wholesale mark-ups and pharmacy mark-ups. The Health Insurance Fund carried
out the supply of medicines on the Positive list by international tenders until 2005.
The reference pricing was introduced in 2007 and it took into consideration the
Purchasing Parity Power. The statistical analysis of the cost of treatment for se-
lected health conditions compared with the average monthly wages, expressed as
working hours shows that less working hours are needed to purchase medicines
for all clinical conditions in 2010 compared to 2005. There is statistically significant
difference in the working hours needed to purchase medicines between 2010 and
2005 (Wilcoxon Matched Pairs Test: Z  2240, p  0, 0250). The better financial
affordability of medicines in 2010 is a result of partly lower medicines prices, but
predominantly a result of higher monthly wages. CONCLUSIONS: The analysis
reveals the positive impact of medicines price control and reference pricing on
medicines affordability. The number of working hours needed to purchase a month
of treatment decreased.
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OBJECTIVES: To evaluate the association of knowledge and medication adherence
with glycemic control in patients with diabetes mellitus type 2. METHODS: The
research was shaped as a cross-sectional, investigational study. Convenient sam-
pling was done to identify a cohort of 540 diabetic patients attending diabetes clinic
of Hospital Pulau Pinang, Penang, Malaysia. A previously validated knowledge test
and medication adherence scale was used for data collection. Patients’ medical
records were reviewed for haemoglobin A1C (HbA1C) levels and other disease-
related information.RESULTS: Five hundred five patients were included in the final
analysis, with a mean age of 58.15 years (SD9.16) with 50.7% males having mean
HbA1C of 7.94 (SD1.61). Knowledge scores ranged from 0 to 14, with mean scores
of 7.44 (SD3.08). Medication adherence scores ranged from 0 to 8 with mean
scores of 6.11 (SD1.66). HbA1C was found to be significantly lower in patients with
higher level knowledge and higher level of medication adherence (p0.05). Signif-
icant correlations were found between the three variables HbA1C, Knowledge and
adherence (p0.05). Combined therapy, higher diabetes knowledge and higher
medication adherence were statistically predictors of good glycemic control.
CONCLUSIONS: There is a high prevalence of poor glycemic control among pa-
tients in this study. This study revealed that knowledge and adherence are among
the modifiable factors that are associated with better glycemic control.
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OBJECTIVES: To evaluate the medication adherence and general diabetes knowl-
edge among patients with type 2 diabetes and to assess the relationship of knowl-
edge with medication adherence of patients. METHODS: A cross-sectional study
design was conducted among convenience sample of 505 type 2 diabetic outpa-
tients in the Diabetes Clinic of the Penang General Hospital, Penang, Malaysia from
November 2009 to April 2010. Patients with diabetes type 2 were asked to complete
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